Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Other Working Capital Changes: 2020-2024

Historic Other Working Capital Changes for Entrada Therapeutics (TRDA) over the last 5 years, with Dec 2024 value amounting to -$119.8 million.

  • Entrada Therapeutics' Other Working Capital Changes rose 97.53% to -$419,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$53.4 million, marking a year-over-year increase of 49.16%. This contributed to the annual value of -$119.8 million for FY2024, which is 185.59% down from last year.
  • Latest data reveals that Entrada Therapeutics reported Other Working Capital Changes of -$119.8 million as of FY2024, which was down 185.59% from $140.0 million recorded in FY2023.
  • In the past 5 years, Entrada Therapeutics' Other Working Capital Changes ranged from a high of $140.0 million in FY2023 and a low of -$119.8 million during FY2024.
  • Over the past 3 years, Entrada Therapeutics' median Other Working Capital Changes value was $14.0 million (recorded in 2022), while the average stood at $11.4 million.
  • Its Other Working Capital Changes has fluctuated over the past 5 years, first spiked by 2,064.95% in 2021, then slumped by 185.59% in 2024.
  • Yearly analysis of 5 years shows Entrada Therapeutics' Other Working Capital Changes stood at $311,000 in 2020, then skyrocketed by 2,064.95% to $6.7 million in 2021, then surged by 108.26% to $14.0 million in 2022, then skyrocketed by 898.26% to $140.0 million in 2023, then crashed by 185.59% to -$119.8 million in 2024.